Oncology
The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?
Find out
the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.
Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more.
Show Less
Read more
Fc Epsilon RI Signaling Pathway in Oncology Drug Pipeline Update 2013
Fc epsilon RI-mediated signaling pathways in mast cells are initiated by the interaction of antigen (Ag) with IgE bound to the extracellular domain of the alpha chain of Fc epsilon RI. The activation...
April
2013
EUR 1,499USD 1,960GBP 1,263AUD 2,085JPY 191,934SEK 12 977CHF 1'844CAD 2,038
RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2013
Potentially any disease-causing gene, cell type or tissue can be targeted with miRNA, RNAi or siRNA, including those not ’druggable’ with small molecules or protein-based therapies.
There are today...
April
2013
EUR 999USD 1,306GBP 842AUD 1,390JPY 127,913SEK 8 649CHF 1'229CAD 1,358
Analytical Tool - Leukemia
"Analytical Tool - Leukemia" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in leukemia R&D and business development. It is at the same time a map of...
April
2013
EUR 3,100USD 4,053GBP 2,612AUD 4,313JPY 396,928SEK 26 837CHF 3'814CAD 4,214
Analytical Tool - Lymphoma
"Analytical Tool: Lymphoma" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in lymphoma R&D and business development. It is also a map of the research...
April
2013
EUR 3,100USD 4,053GBP 2,612AUD 4,313JPY 396,928SEK 26 837CHF 3'814CAD 4,214
Chemokine Signaling Pathway in Cancer Drug Pipeline Update 2013
Inflammatory immune response requires the recruitment of leukocytes to the site of inflammation upon foreign insult. Chemokines are small chemoattractant peptides that provide directional cues for the...
April
2013
EUR 1,499USD 1,960GBP 1,263AUD 2,085JPY 191,934SEK 12 977CHF 1'844CAD 2,038
PI3K-Akt Signaling Pathway in Cancer Drug Pipeline Update 2013
The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation,...
April
2013
EUR 1,999USD 2,614GBP 1,685AUD 2,781JPY 255,955SEK 17 306CHF 2'459CAD 2,718
The MAPK Signaling Pathway in Oncology Drug Pipeline Update 2013
The mitogen-activated protein kinase (MAPK) cascade is a highly conserved module that is involved in various cellular functions, including cell proliferation, differentiation and migration.
There are...
April
2013
EUR 1,499USD 1,960GBP 1,263AUD 2,085JPY 191,934SEK 12 977CHF 1'844CAD 2,038
VEGF Signaling Pathway in Cancer Drug Pipeline Update 2013
There is now much evidence that VEGFR-2 is the major mediator of VEGF-driven responses in endothelial cells and it is considered to be a crucial signal transducer in both physiologic and pathologic...
April
2013
EUR 1,499USD 1,960GBP 1,263AUD 2,085JPY 191,934SEK 12 977CHF 1'844CAD 2,038
Epigenetic Therapy in Oncology Drug Pipeline Update 2013
Improper gene activation or silencing by loss of epigenetic control can lead to aberrant gene expression that can drive the development of diseases such as cancer, autoimmunity, diabetes, or neurological...
April
2013
EUR 999USD 1,306GBP 842AUD 1,390JPY 127,913SEK 8 649CHF 1'229CAD 1,358
Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2013
Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified...
April
2013
EUR 1,499USD 1,960GBP 1,263AUD 2,085JPY 191,934SEK 12 977CHF 1'844CAD 2,038
Gap Junctions in Oncology Drug Pipeline Update 2013
Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels',...
April
2013
EUR 1,499USD 1,960GBP 1,263AUD 2,085JPY 191,934SEK 12 977CHF 1'844CAD 2,038
GnRH Signaling Pathway in Oncology Drug Pipeline Update 2013
Gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus acts upon its receptor in the anterior pituitary to regulate the production and release of the gonadotropins, LH and FSH.
There...
April
2013
EUR 1,499USD 1,960GBP 1,263AUD 2,085JPY 191,934SEK 12 977CHF 1'844CAD 2,038
Viral Carcinogenesis Drug Pipeline Update 2013
There is a strong association between viruses and the development of human malignancies. We now know that at least six human viruses, Epstein-Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus...
April
2013
EUR 1,499USD 1,960GBP 1,263AUD 2,085JPY 191,934SEK 12 977CHF 1'844CAD 2,038
Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2013
Cytokines are soluble extracellular proteins or glycoproteins that are crucial intercellular regulators and mobilizers of cells engaged in innate as well as adaptive inflammatory host defenses, cell...
April
2013
EUR 1,499USD 1,960GBP 1,263AUD 2,085JPY 191,934SEK 12 977CHF 1'844CAD 2,038
mTOR Signaling Pathway in Oncology Drug Pipeline Update 2013
The mammalian target of rapamycin (mTOR) is an intracellular kinase that controls the production of proteins through its regulation of translational machinery. mTOR-activated proteins promote several...
April
2013
EUR 1,499USD 1,960GBP 1,263AUD 2,085JPY 191,934SEK 12 977CHF 1'844CAD 2,038
FSH Signaling Pathway in Oncology Drug Pipeline Update 2013
Follicle stimulating hormone (FSH) binds to FSH-receptor which is coupled to Gs protein that in turn activates cAMP dependent protein kinases (PKA) and thus triggers FSH signaling which continues further...
April
2013
EUR 1,499USD 1,960GBP 1,263AUD 2,085JPY 191,934SEK 12 977CHF 1'844CAD 2,038
Leptin Signaling Pathway in Oncology Drug Pipeline Update 2013
The binding of Leptin to its receptor, LEPR induces various signaling modules such as JAK/STAT, RAS/RAF/MAPK, IRS/PI-3K and AMPK/ACC.
There are today 246 companies plus partners developing 340 Leptin...
April
2013
EUR 1,499USD 1,960GBP 1,263AUD 2,085JPY 191,934SEK 12 977CHF 1'844CAD 2,038
Cancer Stem Cells Drug Pipeline Update 2013
Treatments designed to target and destroy cancer stem cells may come to revolutionize how we treat cancer. This unique product covers both explicit cancer stem cell drug development and cancer drugs...
April
2013
EUR 1,499USD 1,960GBP 1,263AUD 2,085JPY 191,934SEK 12 977CHF 1'844CAD 2,038
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2013
Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. However, these three successful drugs are just...
April
2013
EUR 1,499USD 1,960GBP 1,263AUD 2,085JPY 191,934SEK 12 977CHF 1'844CAD 2,038
Breast Cancer Drug Pipeline Update 2013
Breast cancer is the leading cause of cancer-related mortality among women worldwide. High unmet needs still persist for this tumor type. Despite recent drug approvals in the adjuvant and metastatic...
April
2013
EUR 1,499USD 1,960GBP 1,263AUD 2,085JPY 191,934SEK 12 977CHF 1'844CAD 2,038
